Emergent BioSolutions, Inc. (EBS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
$6.81-5.68%
Close 2026-10-30 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
Research Workspace
Put EBS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve full year 2026 revenue between $720M and $760M: Revenue guidance: $645M to $675M.
View ThesisManagement screens weak on capital allocation, earnings delivery, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 68% in its worst 12-month stretch.
View RiskEBS rests on meeting its 2026 revenue goal, with debt refinancing supporting financial flexibility. Q2 FY2026 revenue grew 66% year over year, though the desk records no latest release. That single growth figure cannot establish an accelerating or slowing trend. EBS trades at 5× P/E versus a 16× peer median. The desk says expectations look modest versus its view. The specific break is 2026 revenue guidance of $645M to $675M, below the $720M to $760M full-year goal. Our model puts the next-quarter miss probability near 34%. Peer multiples imply a price about 62% above where it trades; the thesis has broken, and this read is provisional.
Trailing returns as of 2026-10-30. EBS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering EBS (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare EBS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EBS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put EBS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Refinance debt to reduce interest expense and increase financial flexibility
Debt reduction supports financial flexibility objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Threatens: Maintain revenue guidance for 2026
Tough outlook may hinder revenue guidance for 2026.
Advances: Refinance debt to reduce interest expense and increase financial flexibility
Debt repurchase improves financial flexibility and reduces interest expense.
Threatens: Maintain and grow revenue through government contracts and partnerships
Downgrade indicates increased competitive pressures affecting revenue growth.
Threatens: Maintain revenue guidance for 2026
Lower revenue outlook impacts revenue guidance for 2026.
Advances: Maintain revenue guidance for 2026
Broader authorization could significantly boost revenue.